Japan Approves Prolacta's Human Milk Fortifiers as Prescription Drug

Prolacta Bioscience has achieved a significant milestone with the approval of its 100% human milk-based fortifier, PreemieFort® Enteral Solution, as a prescription drug in Japan. The Japanese Ministry of Health, Labour and Welfare endorsed the product for very low birth weight infants and those with specific health conditions. This decision underscores Prolacta's fortifiers' role in neonatal care, supporting the nutritional needs of vulnerable infants.

The approval follows the JASMINE trial, which highlighted improved growth outcomes in infants using Prolacta's fortifiers. Japan, known for its advanced neonatal care, recognizes these fortifiers as critical pharmaceutical-grade solutions in hospitals. The acceptance includes several variants of PreemieFort®, enhancing growth and safety for fragile infants.